Research Group Alumni
|
|
- Kelly Lindsey
- 5 years ago
- Views:
Transcription
1 Research Group Alumni Francesca Buttini Project: Development of novel dry-powder inhaler formulations PhD Completed April 2007 (Collaboration with the University of Parma). Current Post: Lecturer University of Parma Key Publication: Buttini, F., Colombo, P., Wenger, M. P. E., Mesquida, P., Marriott, C., & Jones, S. A. (2008). Back to basics: The development of a simple, homogenous, two-component dry-powder inhaler formulation for the delivery of budesonide using miscible vinyl polymers. Journal of Pharmaceutical Sciences, 97(3), Mine Orlu Project: Investigation into the use of novel nanocarriers PhD Completed February 2008 (Collaboration with University of Istanbul, Galenos). Current Post: Lecturer University College London Key Publication: Gul, M. O., Jones, S. A., Dailey, L. A., Nacer, H., Ma, Y., Sadouki, F., Forbes, B. (2009). A poly(vinyl alcohol) nanoparticle platform for kinetic studies of inhaled particles. Inhalation Toxicology, 21(7), Monica Reid Project: Development of novel topical metered dose aerosol sprays PhD Completed June Current Post: Pharmaceutical Industry Key Publication: Reid, M. L., Brown, M. B., & Jones, S. A. (2008). Manipulation of corticosteroid release from a transiently supersaturated topical metered dose aerosol using a residual miscible co-solvent. Pharmaceutical Research, 25(11), Yanjun Zhao Project: Engineering novel hydrofluoroalkane nanofoams PhD Completed November Current Post: Lecturer Tianjin University Key Publication: Zhao, Y., Moddaresi, M., Jones, S. A., & Brown, M. B. (2009). A dynamic topical hydrofluoroalkane foam to induce nanoparticle modification and drug release in situ. European Journal of Pharmaceutics and Biopharmaceutics, 72(3),
2 Rajeshree Khengar Project: Novel topical ungula formulations. PhD Completed November Current Post: NHS UK Key Publication: Khengar, R. H., Brown, M. B., Turner, R. B., Traynor, M. J., Holt, K. B., & Jones, S. A. (2010). Free radical facilitated damage of ungual keratin. Free Radical Biology and Medicine, 49(5), Hadjer Nacer Project: Harnessing nanotechnology for nasal drug delivery. PhD Completed December Current Post: Health Foundation Key Publication: Gul, M. O., Jones, S., Dailey, L. A., Nacer, H., Ma, Y., Sadouki, F., Hider, R., Araman, A. & Forbes, B. A poly(vinyl alcohol) nanoparticle platform for kinetic studies of inhaled particles. (2009). Inhalation Toxicology, 21 (7) Sarah Fiala Project: Novel eutectic compositions for topical drug delivery PhD Completed March 2010 Current Post: Lecturer University of Algiers Key publication: Fiala, S., Brown, M. B., & Jones, S. A. (2011). Dynamic in-situ eutectic formation for topical drug delivery. Journal of Pharmacy and Pharmacology, 63(11), Kirsten Staff Project: Delivery of inorganic agents into the skin PhD Completed June 2010 Current Post: Lecturer University of South Australia Key publication: Staff, K., Brown, M. B., Chilcott, R. P., Hider, R. C., Jones, S. A., & Kong, X. L. (2011). Ga(III) complexes-the effect of metal coordination on potential systemic absorption after topical exposure. Toxicology Letters, 202(3), Mojgan Moddaresi Project: Novel cosmetic formulations derived from natural sources Completed June 2010 Current Post: Cosmetics Innovations & Technologies
3 Key publication: Moddaresi, M., Tamburic, S., Williams, S., Jones, S. A., Zhao, Y., & Brown, M. B. (2009). Effects of lipid nanocarriers on the performance of topical vehicles in vivo. Journal of Cosmetic Dermatology, 8(2), Daniel Wood Project: Development of a novel self-assembling thermoregulation device PhD Completed Sep 2010 Current Post: MedPharm UK Ltd Key publication: Wood, D. G., Brown, M. B., & Jones, S. A. (2012). Understanding heat facilitated drug transport across human epidermis. European Journal of Pharmaceutics and Biopharmaceutics, 81(3), Faiza Benaouda Project: Novel supersaturated systems for transdermal drug delivery PhD Completed Sep 2010 Current Post: Post-Doctoral Post at King s Key publication: Benaouda, F., Brown, M. B., Ganguly, S., Jones, S. A., & Martin, G. P. (2012). Discriminating the molecular identity and function of discrete supramolecular structures in topical pharmaceutical formulations. Molecular Pharmaceutics, 9(9), Samantha Gann Project: Zinc as an antimicrobial agent PhD Completed Dec 2010 Current Post: GSK UK Key publication: In preparation Iris Palmer Project: The development of a novel powder formulation for topical drug delivery PhD Completed Dec 2010 Current Post: Unknown Key publication: N/A
4 Fethi Sadouki Project: Poly-vinyl nanoparticles for the administration of antimicrobials to the lung PhD Completed Jan 2012 Current Post: Unkown Key publication: Khanbeigi, R. A., Kumar, A., Sadouki, F., Lorenz, C., Forbes, B., Dailey, L. A., Collins, H. The delivered dose: Applying particokinetics to in vitro investigations of nanoparticle internalization by macrophages Journal of Controlled Release. 162, 2, Aateka Patel Project: Disposition of ion pair pharmaceutical salts in the lung PhD Completed Dec 2013 Current Post: Post Doctoral Researcher at King s College London Key publication: Patel, A., Keir, S.D., Brown, M.B., Hider, R., Jones, S.A., Page, C.P. Using Salt Counterions to Modify β2agonist Behavior in Vivo (2016) Molecular Pharmaceutics, 13 (10), pp Annamaria Baraldi and Sebastien Guesne Project: Investigation into the properties of healthy and diseased human nails for the successful treatment of nail disorders Post-doctoral project completed Sep 2013 Current Post: Post Doctoral Researcher at Leeds University Key publication: Baraldi, A., Jones, S.A., Guesné, S., Traynor, M.J., McAuley, W.J., Brown, M.B., Murdan, S. Human Nail Plate Modifications Induced by Onychomycosis: Implications for Topical Therapy (2015) Pharmaceutical Research, 32 (5), pp Marie Christie Jones Project: Inhaled nanomaterials Current Post: Lecturer at Birmingham University Key publication: Jones, M.-C., Jones, S.A., Riffo-Vasquez, Y., Spina, D., Hoffman, E., Morgan, A., Patel, A., Page, C., Forbes, B., Dailey, L.A. Quantitative assessment of nanoparticle surface hydrophobicity and its influence on pulmonary biocompatibility (2014) Journal of Controlled Release, 183 (1), pp
5 Jasminder Chana Project: Nanoparticles for inhaled drug delivery PhD Completed Jan 2014 Current Post: Post Doctoral Researcher at King s College London Key publication: Chana, J., Forbes, B., Jones, S.A. Triggered-release nanocapsules for drug delivery to the lungs (2015) Nanomedicine: Nanotechnology, Biology, and Medicine, 11 (1), pp Ricardo Inacio Project: The influence of Barometric Pressure Changes upon Xenobiotic Penetration Current Post: Project Manager Kucept Ltd, UK Key publication: Inacio, R., Poland, S., Cai, X.J., Cleary, S.J., Ameer-Beg, S., Keeble, J., Jones, S.A. The application of local hypobaric pressure - A novel means to enhance macromolecule entry into the skin (2016) Journal of Controlled Release, 226, pp Jesmine Cai Project: Self-Assembling Nanomaterials for Topical Drug Delivery Current Post: Unknown Key publication: Cai, X.J., Woods, A., Mesquida, P., Jones, S.A. Assessing the Potential for Drug-Nanoparticle Surface Interactions to Improve Drug Penetration into the Skin (2016) Molecular Pharmaceutics, 13 (4), pp Hanpeng Chen Project: Triggered mucus penetrating delivery systems for inhaled drug delivery Current Post: Pharmaceutical Industry China Key publication: Chen, H., Woods, A., Forbes, B., Jones, S. Controlled drug release from lungtargeted nanocarriers via chemically mediated shell permeabilization (2016) International Journal of Pharmaceutics, 511 (2), pp
EVE 491/591 Toxicology. Toxicant Entry into the Body 2/19/2018. Absorption and Fate of a Toxicant
EVE 491/591 Toxicology Lecture #7 1. Absorption of Toxicants 2. Case study Part VI Toxicant Entry into the Body Toxicants must defeat barriers to absorption The respiratory system The digestive system
More informationChallenges in Nonclinical Development of Inhalation Drug Products
Challenges in Nonclinical Development of Inhalation Drug Products Luqi Pei, Ph.D. Senior Pharmacologist DPARP, CDER August 6, 2015 Rockville, MD Disclaimer This speech reflects the views of the speaker
More informationCurrent Challenges and Opportunities in Demonstrating Bioequivalence
Current Challenges and Opportunities in Demonstrating Bioequivalence Gur Jai Pal Singh, Ph.D. Watson Laboratories, Inc. Corona, California, USA Demonstrating Bioequivalence of Locally Acting Orally Inhaled
More informationNovel drug delivery system. Nanos-in-Micros
Novel drug delivery system Nanos-in-Micros Janne Raula The annual symposium of the Finnish Society of Physical Pharmacy February 9 th, 2012 Medicinal treatment Indications -Neurosurgery -General surgery
More informationDISSOLUTION TESTING - Exploring the Link Between Particle Size & Dissolution Behavior for OINDPs
Issue: March 2016, Posted Date: 3/1/2016 DISSOLUTION TESTING - Exploring the Link Between Particle Size & Dissolution Behavior for OINDPs INTRODUCTION In the development of orally inhaled and nasal products
More informationPHARMACEUTICAL SCIENCES (PHM SCI)
Pharmaceutical Sciences (PHM SCI) 1 PHARMACEUTICAL SCIENCES (PHM SCI) PHM SCI 310 DRUGS AND THEIR ACTIONS Introduces students to the biological effects of drugs on human health. Emphasis on how drugs,
More informationMıCELLES AS NANOSıZED CARRıERS FOR SKıN DELıVERY OF DRUGS. Sevgi Güngör
MıCELLES AS NANOSıZED CARRıERS FOR SKıN DELıVERY OF DRUGS Sevgi Güngör Istanbul University, Faculty of Pharmacy, Department of Pharmaceutical Technology 4 th International Conference on Nanotek&Expo,01-03
More informationCell Membranes, Epithelial Barriers and Drug Absorption p. 1 Introduction p. 2 The Plasma Membrane p. 2 The phospholipid bilayer p.
Cell Membranes, Epithelial Barriers and Drug Absorption p. 1 Introduction p. 2 The Plasma Membrane p. 2 The phospholipid bilayer p. 3 Dynamic behaviour of membranes p. 4 Modulation of membrane fluidity
More informationBiopharmaceutics Dosage form factors influencing bioavailability Lec:5
Biopharmaceutics Dosage form factors influencing bioavailability Lec:5 Ali Y Ali BSc Pharmacy MSc Industrial Pharmaceutical Sciences Dept. of Pharmaceutics School of Pharmacy University of Sulaimani 09/01/2019
More informationIncreasing access to oxytocin for the prevention of postpartum haemorrhage: Inhaled Oxytocin A Phase I Study. Disala Fernando, MD
Increasing access to oxytocin for the prevention of postpartum haemorrhage: Inhaled Oxytocin A Phase I Study Disala Fernando, MD The following clinical trial (NCT02542813) was funded entirely by the pharmaceutical
More information1.2 Nano- or microencapsulation as a rich source of delivery of functional components 3
1 Overview of Nano- and Microencapsulation for Foods 1 Hae-Soo Kwak 1.1 Introduction 1 1.2 Nano- or microencapsulation as a rich source of delivery of functional components 3 1.3 Wall materials used for
More informationPeptiCaps Your nano-solution for healthy skin
PeptiCaps Your nano-solution for healthy skin PeptiCaps: The nano-solution for healthy skin THE PROBLEM Natural active ingredients have beneficial effect to have healthy skin Degradation loss of its effect
More informationThe influence of lactose particle size on dry powder inhalation performance
The influence of lactose particle size on dry powder inhalation performance MCC Starch Lactose Inhalation Superdisintegrants 1 Introduction In most dry powder inhalation (DPI) formulations carriers are
More informationBuccal naloxone. Professor Sir John Strang & Rebecca McDonald National Addiction Centre, King s College London & SLaM NHS FT
Buccal naloxone Professor Sir John Strang & Rebecca McDonald National Addiction Centre, King s College London & SLaM NHS FT Declarations RM RM has undertaken an unpaid student industry placement with Mundipharma
More informationIvax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence
Ivax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence Clinical and cost-effectiveness of QVAR for the treatment of chronic asthma in adults and children
More informationEncapsulated chlorhexidine for sustained release/antibacterial effects
Encapsulated chlorhexidine for sustained release/antibacterial effects Fabrice Pirot a, Yves Ducini b, Gérard Trouvé b a: Laboratoire de pharmacie galénique industrielle Faculté de Pharmacie de Lyon www.fripharm.com
More informationMaria João Silva H. Louro 1, T. Borges 2, J. Lavinha 1, J.M. Albuquerque 1
Maria João Silva H. Louro 1, T. Borges 2, J. Lavinha 1, J.M. Albuquerque 1 1 National Institute of Health Dr. Ricardo Jorge 2 General-Directorate of Health, Lisbon, Portugal Venice.,10-03-2015 The number
More informationCaption: The equipment required for testing Fluticasone Propionate (FP) Inhalation Powder in line with a new product-specific monograph (USP36-NF31).
Product-specific FDA guidance, and product-specific pharmacopeial monographs, point to the use of test equipment, some of which isn t included in the general USP/Ph. Eur. chapters for orally inhaled products
More informationDrug Delivery: Improving Bioavailability and Overcoming Toxicity. Matthew J. Medina Biology of Toxins Spring 2012
Drug Delivery: Improving Bioavailability and Overcoming Toxicity Matthew J. Medina Biology of Toxins Spring 2012 Introduction Utilizing nanomaterials has gained considerable interest when it comes to improving
More information905 UNIFORMITY OF DOSAGE UNITS
Change to read: 905 UNIFORMITY OF DOSAGE UNITS [ NOTE In this chapter, unit and dosage unit are synonymous. ] To ensure the consistency of dosage units, each unit in a batch should have a drug substance
More informationPRACTICES OF COATING COLLECTION SURFACES OF CASCADE IMPACTORS: A SURVEY OF MEMBERS OF THE EUROPEAN PHARMACEUTICAL AEROSOL GROUP (EPAG)
PRACTICES OF COATING COLLECTION SURFACES OF CASCADE IMPACTORS: A SURVEY OF MEMBERS OF THE EUROPEAN PHARMACEUTICAL AEROSOL GROUP () J.P. Mitchell on behalf of members of the European Pharmaceutical Aerosol
More informationREFERENCES OVERVIEW ADVANTAGES AEROSOLS. Aerosols. and Foams
COMMONWEALTH OF AUSTRALIA Copyright Regulations 1969 WARNING This material has been reproduced and communicated to you by or on behalf of Monash University pursuant to Part VB of the Copyright Act 1968
More informationFDA Expectations and Evaluation of Inhalation Toxicology Studies
FDA Expectations and Evaluation of Inhalation Toxicology Studies Presented by Timothy McGovern, Ph.D. SciLucent, LLC Herndon, Virginia Development of inhalation products has unique regulatory aspects My
More informationThe Need - Skin Barrier Protection. The Need - Skin Biochemical Balance
NSPS by Asta Technologies, Ltd. The microalgae Porphyridium Cruentum excretes Natural Sulfated Polysaccharides as a protective layer which enables it to flourish even in harsh and extreme conditions. Extensive
More informationNonclinical Safety Evaluation of Inhalation Drug Products
Nonclinical Safety Evaluation of Inhalation Drug Products February 13, 2002 Life Science Research Organization Bethesda, Maryland Luqi Pei, Ph.D. Division of Pulmonary and Allergy Drug Products Center
More informationADVANCIA : A TRUE PLATFORM & INNOVATIVE SYSTEM OFFERING EFFICIENT NASAL DOSE DELIVERY
ADVANCIA : A TRUE PLATFORM & INNOVATIVE SYSTEM OFFERING EFFICIENT NASAL DOSE DELIVERY Millions of people suffering from allergic rhinitis use nasal sprays manufactured by Nemera every day. In this article,
More informationCFCs in inhalers for asthma and COPD
CFCs in inhalers for asthma and COPD What s happening? 2009 United Nations Environment Programme Developed in association with the National Asthma Council Australia Supported by the Multilateral Fund for
More informationSchool of Pharmacy Faculty of Medicine The Chinese University of Hong Kong. Transdermal Drug Delivery System
Workshop in Celebration of 25 th Anniversary of the School of Pharmacy Biopharmaceutics of Modified Release Products and Challenging Drug Molecules Design and Regulatory Assessment of Transdermal Drug
More informationCOMMENTS. Submitted by The International Pharmaceutical Aerosol Consortium
COMMENTS on a draft Guidance for Industry Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products Chemistry, Manufacturing, and Controls Documentation (Docket No. 99D-1454) Submitted by
More informationCHAPTER-I DRUG CHARACTERIZATION & DOSAGE FORMS
CHAPTER-I DRUG CHARACTERIZATION & DOSAGE FORMS by: j. jayasutha lecturer department of pharmacy practice Srm college of pharmacy srm university DRUG CHARACTERIZATION: Pre-formulation studies will attempt
More informationInhalation Product Research at FDA
Inhalation Product Research at FDA Changning Guo Ph. D., Chemist Division of Pharmaceutical Analysis FDA/CDER/OPS/OTR 2016 GPhA CMC workshop, May 17, 2016 Disclaimer: This presentation reflects the views
More informationTHEORY: Modern Pharmaceutical Analytical Techniques (MPH-101) Drug Delivery System (MPH-102) Modern Pharmaceutics (MPH-103) Regulatory Affairs (MPH-10
Modern Pharmaceutical Analytical Techniques (MPH-101) Drug Delivery System (MPH-102) Modern Pharmaceutics (MPH-103) Regulatory Affairs (MPH-104) PRACTICAL: Pharmaceutics (MPH-105) Seminar/Assignment (MPH-106)
More informationChemical Surface Transformation 1
Chemical Surface Transformation 1 Chemical reactions at Si H surfaces (inorganic and organic) can generate very thin films (sub nm thickness up to µm): inorganic layer formation by: thermal conversion:
More informationEnhanced delivery methods for greater efficacy
On-Line Formulation Training - Anywhere In The World - Enhanced delivery methods for greater efficacy Belinda Carli Director, Institute of Personal Care Science Image showing absorbance in the outer stratum
More informationDrug/Device Combination Products: Bioequivalence
Drug/Device Combination Products: Bioequivalence Three stories:. The story of Nasal and Inhalation Product BE 2. The story of the Generic Auto-Injector 3. The story of User Interface Considerations Bioequivalence
More informationImproved Weatherability of Outdoor Wood Stains using Nanotechnology
Improved Weatherability of Outdoor Wood Stains using Nanotechnology Roger Cayton, Patrick G. Murray, David Nelson, and Ryan Ostrowski Nanophase Technologies Corporation, US Introduction There is no question
More informationSmart asthma therapy. Patient information Spacer inhaling aid for metered-dose aerosol inhalers
FF Smart asthma therapy Patient information Spacer inhaling aid for metered-dose aerosol inhalers :: Metered-dose inhalers coordination technique In the treatment of asthma and COPD the medications are
More informationUse of Math Modelling to Understand Delivery of Biopharmaceutical Molecules to the Lung
Use of Math Modelling to Understand Delivery of Biopharmaceutical Molecules to the Lung Nia Stevens 9 th November 2016 Thanks to Richard Kaye, James Mitchell, Dave Prime at GSK Bahman Asgharian and Owen
More informationInformation for Patients. Inhaler devices for routine treatment of chronic asthma in older children (aged 5-15 years)
Information for Patients Inhaler devices for routine treatment of chronic asthma in older children (aged 5-15 years) March 2002 Further information Further information on NICE and the full guidance on
More informationMetered Dose Inhaler Technology
Metered Dose Inhaler Technology Edited by Tol S. Purewal and David J. W. Grant Interpharm Press, Inc. Buffalo Grove, Illinois Contents 1. INTRODUCTION 1 T. S. Purewal Definition of the Metered Dose Inhaler
More informationConsiderations for Inhalation Safety Assessment: Approaches and Application
Considerations for Inhalation Safety Assessment: Approaches and Application Madhuri Singal, PhD, RRT, DABT Inhalation Toxicologist, Senior Consumer Safety Associate Reckitt Benckiser, LLC CIR Expert Panel
More informationI. Subject: Medication Delivery by Metered Dose Inhaler (MDI)
I. Subject: Medication Delivery by Metered Dose Inhaler (MDI) II. Policy: Aerosol medication administration by metered dose inhaler will be performed upon a physician's order by Respiratory Therapy personnel.
More informationNanoparticles: Conclusions. 1. Nanoparticles are not new. Six messages. -health hazards and risks. Nano-1. Nano-1
Nanoparticles: -health hazards and risks Kaarle Hämeri University of Helsinki/ Finnish Institute of Occupational Health Conclusions There is no evidence on the significant health and environmental risks
More informationNanoparticles: -health hazards and risks. Nano-1. Kaarle Hämeri University of Helsinki/ Finnish Institute of Occupational Health
Nanoparticles Health hazards and risks, Kaarle Hämeri 8.11.2010 Nano-1 Nanoparticles: -health hazards and risks Kaarle Hämeri University of Helsinki/ Finnish Institute of Occupational Health Conclusions
More informationSELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS. Dr. Jay T. Holt, Ph.D., Sr. Director, Inhalation & Analytical
SELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS Dr. Jay T. Holt, Ph.D., Sr. Director, Inhalation & Analytical www.cirruspharm.com February 2014 INTRODUCTION Cirrus, a Kemwell company, is frequently
More informationLung Imaging in Inhaled Product Development. Lea Ann Dailey, PhD DDL 05 December 2012
Lung Imaging in Inhaled Product Development Lea Ann Dailey, PhD DDL 05 December 2012 The Drugs in the Lung Consortium Network Data Sharing Research King s College London GSK Pfizer Novartis Astra Zeneca
More informationEffect of Atmospheric Plasma on the Surface Area of Powdered Whey Protein Isolate
Discipline Medical Keywords Plasma Atmospheric Plasma Whey Protein Observation Type Standalone Nature Standard Data Submitted Jun 19th, 2017 Published Sep 13th, 2017 MATTERS 22/30 Effect of Atmospheric
More informationCERENIS Therapeutics acquires LYPRO Biosciences expanding its HDL strategy into immuno-oncology and chemotherapeutic drug delivery
Press release CERENIS Therapeutics acquires LYPRO Biosciences expanding its HDL strategy into immuno-oncology and chemotherapeutic drug delivery Combining LYPRO Biosciences NanoDisk technology with CERENIS
More informationRisk Assessment for coating applications
Facutly of Mechanical Engineering Institute of Process Engineering and Environmental Technology, Research Group Mechanical Process Engineering Experimental Study Risk Assessment for coating applications
More informationDevelopment of a Dry Powder Multi-dose Inhaler using Computational Modeling
ENGINEER - Vol. XXXXII, No. 03, pp. [57-65], 2009 The Institution of Engineers, Sri Lanka Development of a Dry Powder Multi-dose Inhaler using Computational Modeling M.A.D.A.Sudeera, V.P.C.Dassanayake,
More informationT U R B I S C A N. Automatic stability analyses for pharmaceutics
Automatic stability analyses for pharmaceutics Stability of pharmaceutics o Pharmaceutical formulations suspension (eye drops, drug powder, ) emulsion (cream, lotion, parenteral emulsion, ) aerosol (pmdi,
More information: Application of Nanotechnology to Cosmetics and Foods
LIVE INTERACTIVE LEARNING @ YOUR DESKTOP : Application of Nanotechnology to Cosmetics and Foods Robert L. Bronaugh, Ph.D. Director, Cosmetics Staff Office of Cosmetics and Colors Tuesday, November 24,
More informationSafer by design, transparent, UV-absorbing ZnO nanorods with minimal genotoxicity
Safer by design, transparent, UV-absorbing ZnO nanorods with minimal genotoxicity Georgios A. Sotiriou, Christa Watson, Kim M. Murdaugh, Alison Elder 1 and Philip Demokritou Center for Nanotechnology and
More informationTopical Preparations
Topical Preparations One of the functions of the skin is to protect the internal body components against the external environment and thus to control the passage of chemicals into and out of the body.
More informationNovel Application of an Old Excipient L-Leucine- Improving Physical and. Aerosolization Stability of Spray Dried Amorphous DPI Formulations.
1 Novel Application of an Old Excipient L-Leucine- Improving Physical and Aerosolization Stability of Spray Dried Amorphous DPI Formulations. Nivedita Shetty 1, Dmitry Zemlyanov 2, Qi (Tony) Zhou 1 1 Department
More informationUnderstanding Regulatory Global Requirements for Nasal Drug Products. Julie D. Suman, Ph.D. April 8, 2016
Understanding Regulatory Global Requirements for Nasal Drug Products Julie D. Suman, Ph.D. April 8, 2016 AGENDA NDA vs ANDA Regulatory Approaches for Bioequivalence (BE) FDA Drug Specific Guidances FDA,
More informationBeclometasone dipropionate (BDP) Prophylactic management of mild, moderate or severe asthma in adults
CLENIL MODULITE Beclometasone dipropionate (BDP) Prophylactic management of mild, moderate or severe asthma in adults Corticosteroids for the treatment of chronic asthma in adults and children aged 12
More informationAssessment of Human Pharmaceutical Products Registered in Kenya by Route of Administration and Type of Dosage Form
38 East and Central African Journal of Pharmaceutical Sciences Vol. 15 (2012) 38-46 Assessment of Human Pharmaceutical Products Registered in Kenya by Route of Administration and Type of Dosage Form N.N.
More informationOccupational asthma. Dr Gordon Parker NHS. Consultant / Honorary Lecturer in Occupational Medicine. Lancashire Teaching Hospitals NHS Foundation Trust
Occupational asthma Dr Gordon Parker Consultant / Honorary Lecturer in Occupational Medicine Lancashire Teaching Hospitals NHS Foundation Trust NHS The good old bad old days Coal workers pneumoconiosis
More informationTREAT U is a spin-off from the University of Coimbra, founded in January 2010, and headquartered in Coimbra, Portugal.
TREAT U is a spin-off from the University of Coimbra, founded in January 2010, and headquartered in Coimbra, Portugal. MISSION & VISION Our mission is to develop more effective strategies and safer products
More informationLymphatic targeting drug delivery system and tumor treatment. Yu Xiao*
2018 International Conference on Medicine, Biology, Materials and Manufacturing (ICMBMM 2018) Lymphatic targeting drug delivery system and tumor treatment Yu Xiao* Department of Pharmacy, Sichuan University,
More informationDevice Change Management for Inhaled Products. Loy Britto, Ph.D. GlaxoSmithKline ISAM Congress Munich 2015
Device Change Management for Inhaled Products Loy Britto, Ph.D. GlaxoSmithKline ISAM Congress Munich 2015 Topics to be covered Update on ISO/TC 084/WG 15: Guidelines for development of drug products- Quality
More informationIngredient Product Information File FARMAL MS 6135
FARMAL MS 6135 1. Product identity INCI Name Chemical name Description Intended function Appearance CAS number 374539-60-3 EC number - Source Manufacturing Country of Origin Manufacturing process Shelf
More informationAnnals of West University of Timisoara
Annals of West University of Timisoara Series of Chemistry 19 (1) (2010) 91-96 DETERMINATION OF VALPROATE IN PHARMACEUTICAL PREPARATIONS USING A VALPROATE-SELECTIVE SENSOR Monica Sava, V.A. Chiriac, Dana
More informationERC TeleSeminar Series Steven O. Nielsen The University of Texas at Dallas February 7, 2013
ERC TeleSeminar Series Steven O. Nielsen The University of Texas at Dallas February 7, 2013 SRC/SEMATECH Engineering Research Center for Environmentally Benign Semiconductor Manufacturing 1 Outline 1.
More informationInhalation Aerosols. jnforma healthcare. Physical and Biological Basis for Therapy. Second Edition. Edited by. Anthony J. Hickey
Inhalation Aerosols Physical and Biological Basis for Therapy Second Edition Edited by Anthony J. Hickey University of North Carolina Chapel Hill, North Carolina, U.S.A. jnforma healthcare New York London
More informationHARD TWO-PIECE HPMC CAPSULES FOR PHARMACEUTICAL APPLICATIONS IN INHALATION
HARD TWO-PIECE HPMC CAPSULES FOR PHARMACEUTICAL APPLICATIONS IN INHALATION 2 3 QUALICAPS HISTORY Over one hundred years of experience in the manufacturing and filling of hard two-piece capsules Qualicaps
More informationCan wetting and dispersing additives improve the durability of coatings?
Can wetting and dispersing additives improve the durability of coatings? János Hajas BYK-Chemie, Wesel, Germany Topics: WETTING AND DISPERSING ADDITIVE, DURABILITY, CORROSION RESISTANCE 1. Abstracts There
More informationSavesta Herbals is engaged in manufacturing
Savesta Herbals is engaged in manufacturing standardized herbal extracts that synergistically combine the ancient wisdom of Ayurveda with the modern production and QC methods. Our state-of- the- art production
More information1. Module Details PENETRANT TESTING. 2. Module Purpose To enable students to develop a detailed understanding of the
1. Module Details Module name Nominal duration PENETRANT TESTING One and one half modules It is anticipated that a learner holding the prescribed entry level skills will achieve the module purpose in 55
More informationEnsuring the Quality of Some Drug-Device Combination Products - FDA Perspective
Ensuring the Quality of Some Drug-Device Combination Products - FDA Perspective PQRI Meeting, Rockville, MD - 2017 Ramesh Raghavachari, Ph.D. Chief, Branch I, DPMA I, OLDP OPQ 03/23/2017 OFFICE OF PHARMACEUTICAL
More informationDevelopment of Nutrient Delivery Systems: Ingredients & Challenges
Development of Nutrient Delivery Systems David Julian McClements and Hang Xiao Department of Food Science University of Massachusetts Development of Nutrient Delivery Systems: Ingredients & Challenges
More informationAdditives for waterborne coatings
Additives for waterborne coatings Wernfried Heilen 1 Introduction 2 Wetting- and dispersing additives 2.1 Modes of action 2.1.1 Pigment wetting 2.1.2 Grinding 2.1.3 Stabilisation 2.1.3.1 Electrostatic
More informationTake-Home naloxone: developments and futures. John Strang & Rebecca McDonald National Addiction Centre, King s College London, UK
Take-Home naloxone: developments and futures John Strang & Rebecca McDonald National Addiction Centre, King s College London, UK Overall message Proud of what we have achieved Humble about how much more
More informationB for hydrogen sulfide removal (e.g. in oil exploration) B highly active zinc compound B excellent cost/performance ratio
INDUSTRIAL CHEMICALS Active Zinc Oxides/Zinc Carbonates Direct/Indirect Zinc Oxides Product Composition Applications and Caracteristics Zinc Carbonate RAC Hydrozincite, Zinc Oxide Sulfur Absorption B for
More informationPIPELINE TRENDS AND CHALLENGES IN PULMONARY DELIVERY
PIPELINE TRENDS AND CHALLENGES IN PULMONARY DELIVERY Here, Gunilla Petersson, PhD, Science & Innovation Director, Inhaled Drug Delivery, AstraZeneca, provides an overview of the inhalables sector from
More informationEncapsulation techniques
Loughborough University Institutional Repository Encapsulation techniques This item was submitted to Loughborough University's Institutional Repository by the/an author. Citation: VLADISAVLJEVIC, G.T.,
More informationRECENT ADVANCES IN LIPOSOMAL DRY POWDER INHALER FORMULATIONS FOR PULMONARY DISORDER
RECENT ADVANCES IN LIPOSOMAL DRY POWDER INHALER FORMULATIONS FOR PULMONARY DISORDER Ambikanandan Misra, Professor of Pharmaceutics & Head, Pharmacy Department TIFAC CORE IN NDDS PHARMACY DEPARTMENT FACULTY
More informationDelay Between Actuation and Shaking of a Hydrofluoroalkane Fluticasone Pressurized Metered-Dose Inhaler
Delay Between Actuation and Shaking of a Hydrofluoroalkane Fluticasone Pressurized Metered-Dose Inhaler Ariel Berlinski MD, Dirk von Hollen, John N Pritchard PhD, and Ross HM Hatley PhD BACKGROUND: Inhaled
More informationCitation for published version (APA): Westerman, E. M. (2009). Studies on antibiotic aerosols for inhalation in cystic fibrosis s.n.
University of Groningen Studies on antibiotic aerosols for inhalation in cystic fibrosis Westerman, Elisabeth Mechteld IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF)
More informationEPAG Perspective - Regulatory Advances Related to Nasal Spray Pumps. Dr G.Williams Nasal Drug Delivery Management Forum London, 15 Apr 2010
1 EPAG Perspective - Regulatory Advances Related to Nasal Spray Pumps Dr G.Williams Nasal Drug Delivery Management Forum London, 15 Apr 2010 Overview 2 EPAG, what is it?, background, this project Regulatory
More informationFourth Symposium on Phospholipids in Pharmaceutical Research. 21 st 22 nd, September 2015 Heidelberg, Germany. 3rd Circular
Fourth Symposium on Phospholipids in Pharmaceutical Research 21 st 22 nd, September 2015 Heidelberg, Germany 3rd Circular page 2 Introduction Phospholipids excipients are worldwide being used in many registered
More informationOPTIMISING ANALYTICAL STRATEGIES FOR THE DEMONSTRATION OF BIOEQUIVALENCE IN A GENERIC NEBULISER
OPTIMISING ANALYTICAL STRATEGIES FOR THE DEMONSTRATION OF BIOEQUIVALENCE IN A GENERIC NEBULISER US FDA guidance for the in vitro demonstration of bioequivalence in a generic nebuliser directly references
More informationCharacterisation of hydroxypropyl methylcellulose-bile salts aggregation and its impact on poorly water-soluble drug solubilisation in the gut.
Characterisation of hydroxypropyl methylcellulose-bile salts aggregation and its impact on poorly water-soluble drug solubilisation in the gut. Claudia Pigliacelli School of Pharmacy, University of East
More informationKURARAY POVAL & EXCEVAL
Characteristics Polyvinyl alcohol (PVOH) having varying degree of polymerization and. Recommended Uses Ranging from emulsion polymerization aid to binder for pigments in paper applications. Form supplied
More information2/7/13. Andrea Rhodes, PharmD Undergraduate: Kansas State University and Wichita State University for prepharmacy
Andrea Rhodes, PharmD Undergraduate: Kansas State University and Wichita State University for prepharmacy Graduated from University of Kansas School of Pharmacy in 2005 with Doctorate of Pharmacy Work
More informationElectronic Supporting Information
Electronic Supplementary Material (ESI) for Green Chemistry. This journal is The Royal Society of Chemistry 2018 Electronic Supporting Information Two-phase systems developed with hydrophilic and hydrophobic
More informationBiopharmaceutics of Non-Orally Administrated Drugs
Biopharmaceutics of Non-Orally Administrated Drugs Robert Lionberger, Ph.D. Deputy Director for Science (acting) Office of Generic Drugs, FDA November 21, 2013 AAPS Webinar Opinions expressed in this presentation
More informationBioequivalence Requirements: USA and EU
Bioequivalence Requirements: USA and EU Dr. Nicholas Cappuccino Chair, IGPA Science Committee Global Head of Quality, Dr. Reddy s Laboratories Ltd. 15 th Annual IGPA Conference Kyoto, Japan December 6,
More informationMedicinal Cannabis Dosage Forms in California
Mica Gross President Sante Botanica / COO MDBioLogics Medicinal Cannabis Dosage Forms in California An Overview of Cannabis Dosage Forms Forms of dosage are the specific vehicles by which cannabis, or
More informationLight and X-ray triggered liposomal gene/drug delivery system for cancer therapy
Light and X-ray triggered liposomal gene/drug delivery system for cancer therapy Wei Deng, 1 Wenjie Chen, 2 Sandhya Clement, 1 Anna Guller, 1 Alexander Engel, 3 Ewa Goldys 1 1 The Graduate School of Biomedical
More informationCOPD Device Workshop. Summary. Role of inhaler device in COPD. Why use inhaler device in COPD?
Part 1 Role of inhaler device in COPD COPD Device Workshop Dr Philip Lee Respiratory and Sleep Physician St George Hospital, Sydney Part 2 Part 3 Part 4 Incorrect inhaler technique-adverse clinical outcomes
More informationCapturing lightning In A Bottle
Capturing lightning In A Bottle Featured In: Manufacturing & Capabilities I Facility of the Year I ISPE By Stephen Hall, Senior Director, Engineering, MannKind Corporation; Juergen Martens, Chief Technical
More informationRecommendations for Aerosol Applications of Silicone-Based Materials
Recommendations for Aerosol Applications of Silicone-Based Materials September 2001 Revised March 2018 This document provides information and recommendations relevant to formulating aerosol products containing
More informationThe effect of active and passive smoking on inhaled drugs in respiratory patients
CHAPTER 12 The effect of active and passive smoking on inhaled drugs in respiratory patients G. Invernizzi*, A. Ruprecht*, P. Paredi #, R. Mazza*, C. De Marco*, R. Boffi* *Tobacco Control Unit, National
More informationClinical Trial List
Clinical Trial List 2005 2008 Service Driven. Quality Focused. Global Perspective. Clinical Trial List 2005-2008 1 Pharmacokinetic A Two-Period, Single Dose Pharmacokinetic Study of Three Sustained-Release
More informationEvaluation of wetting and dispersing additives for the use in waterborne anticorrosive paints. Düsseldorf, , Martin Muth
Evaluation of wetting and dispersing additives for the use in waterborne anticorrosive paints Düsseldorf, 12.09.2013, Martin Muth Content 1. Introduction 2. Functionality and chemistry of wetting and dispersing
More informationCHELATES THE MAJOR CLASSES OF CHELATES ARE: Aminopolycarboxylic Acids *NTA. Hydroxycarboxylic Acids. *Citric Acid *Gluconic Acids *Glucoheptonic Acid
Chelate is derived from the word chela, which is the claw of a crab, lobster, scorpion, etc. In our case the metallic ions such as calcium, magnesium, iron, etc. are bound by the claw and kept from reacting
More informationIntracheal antibiotics administration
Intracheal antibiotics administration Jean Chastre, M.D. www.reamedpitie.com Disclosure Conflicts of interest: Consulting or Lecture fees: Bayer, Pfizer, Cubist/Merck, Basilea, Kenta/Aridis, Roche, AstraZeneca/Medimmune
More informationSub-components in Nicotine cessation products?
Sub-components in Nicotine cessation products? Mr Arun Sarda, Director of Quality and Regulatory Affairs Member of the HEITKAMP & THUMANN GROUP Regulatory approval of sub-components in nicotine cessation
More information